Results 51 to 60 of about 80,955 (206)

Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice.

, 2005
Poly(ADP-ribose) polymerase-1 (PARP) inhibitors have been investigated as enhancers of chemotherapy. We recently showed that PARP inhibitor GPI 15427 increases the anti-tumor efficacy of temozolomide (TMZ) in mice. To select a PARP inhibitor for clinical
C. Leonetti, M. Vergati, Tentori, L, J. Zhang, G. Graziani, GRAZIANI, GRAZIA, Vergati, M, TENTORI, LUCIO, M. Scarsella, Graziani, G, A. Muzi, Leonetti, C, and and the Guilford PARP Project Group, Scarsella, M, Muzi, A, Lapidus, RG, MUZI, ALESSIA, L. Tentori, R. G. Lapidus, and the Guilford PARP Project Group, Zhang, J   +20 more
core   +1 more source

Advances and perspectives of PARP inhibitors

Experimental Hematology & Oncology, 2019
Abstract DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive genome instability and catastrophic DNA damage.
Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu, Suxia Luo   +5 more
openaire   +3 more sources

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

, 2023
Prostate cancer harboring BRCA1/2 mutations are often exceptionally sensitive to PARP inhibitors. However, genomic alterations in other DNA damage response genes have not been consistently predictive of clinical response to PARP inhibition.
Sztupinszki, Zsofia, Antoine Simoneau, Simoneau, Antoine, Atish D. Choudhury, Kunihiko Hinohara, Adam S. Kibel, Bin Gui, Xie, Ning, Chao Feng, Szallasi, Zoltan, Takai, Tomoaki, Xiao Bai, Feng, Chao, Fazli, Ladan, Ning Xie, Xuesen Dong, Jia, Li, Kibel, Adam S., Zou, Lee, Takeshi Tsutsumi, Li Jia, Tsutsumi, Takeshi, Miao, Chenkui, Fu Gui, Haruhito Azuma, Tsujino, Takuya, Lee Zou, Azuma, Haruhito, Gui, Fu, Zsofia Sztupinszki, Chenkui Miao, Gui, Bin, Kent W. Mouw, Mouw, Kent W., Ladan Fazli, Zoltan Szallasi, Choudhury, Atish D., Takuya Tsujino, Tomoaki Takai, Hinohara, Kunihiko, Dong, Xuesen, Bai, Xiao   +41 more
core   +1 more source

Dual Inhibitors of PARPs and ROCKs [PDF]

ACS Omega, 2018
Recent network and system biology analyses suggest that most complex diseases are regulated by robust and highly interconnected pathways that could be better modulated by small molecules binding to multiple biological targets. These pieces of evidence recently led to devote efforts on identifying single chemical entities that bind to two different ...
Albert A. Antolín, Jordi Mestres
openaire   +5 more sources

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy

Journal of Ovarian Research
Background The efficacy of subsequent therapy after poly-ADP-ribose polymerase (PARP) inhibitor maintenance treatment has raised concerns. Retrospective studies show worse outcomes for platinum-based chemotherapy after progression of PARP inhibitor ...
Nan Zhang, Hong Zheng, Yunong Gao, Tong Shu, Hongguo Wang, Yan Cai   +5 more
doaj   +1 more source

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsResearch in context

EBioMedicine, 2018
Background: PARP-1 plays a critical role in DNA damage repair and contributes to progression of cancer. To explore the role of PARP-1 in acute myeloid leukemia (AML), we analyzed the expression of PARP-1 in AML and its relation to the clinical prognosis.
Xia Li, Chenying Li, Jingrui Jin, Jinghan Wang, Jiansong Huang, Zhixin Ma, Xin Huang, Xiao He, Yile Zhou, Yu Xu, Mengxia Yu, Shujuan Huang, Xiao Yan, Fenglin Li, Jiajia Pan, Yungui Wang, Yongping Yu, Jie Jin   +17 more
doaj   +1 more source

p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates. [PDF]

PLoS ONE, 2016
The cell cycle inhibitor p21CDKN1A was previously found to interact directly with DNA nick-sensor poly(ADP-ribose) polymerase-1 (PARP-1) and to promote base excision repair (BER).
Ilaria Dutto, Maria Sukhanova, Micol Tillhon, Ornella Cazzalini, Lucia A Stivala, A Ivana Scovassi, Olga Lavrik, Ennio Prosperi   +7 more
doaj   +1 more source

A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer

Сибирский онкологический журнал, 2022
Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert, I. A. Kolomiets, Y. A. Fesik, A. A. Ivanova, N. V. Yunusova, О. N. Churuksaeva   +5 more
doaj   +1 more source

Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1-5

, 2011
Copyright information:Taken from "Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1"http://www.biomedcentral.com/1471-2199/8/96BMC Molecular Biology
Sylvain L Guérin (83633), Serge Desnoyers (83632), Steeve Leclerc (22751), Karine Zaniolo (83631)   +3 more
core   +1 more source

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers

Frontiers in Pharmacology, 2022
PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated excellent inhibitory activity for both PARP1 and PARP2 enzymes.
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen, Xiaoguang Chen   +8 more
doaj   +1 more source